LantheusLNTH
LNTH
About: Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Employees: 834
0
Funds holding %
of 6,812 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
69% more first-time investments, than exits
New positions opened: 103 | Existing positions closed: 61
67% more funds holding in top 10
Funds holding in top 10: 6 [Q2] → 10 (+4) [Q3]
60% more call options, than puts
Call options by funds: $93.8M | Put options by funds: $58.8M
39% more capital invested
Capital invested by funds: $5.57B [Q2] → $7.71B (+$2.15B) [Q3]
9% more funds holding
Funds holding: 449 [Q2] → 491 (+42) [Q3]
1.45% more ownership
Funds ownership: 100.1% [Q2] → 101.55% (+1.45%) [Q3]
11% less repeat investments, than reductions
Existing positions increased: 159 | Existing positions reduced: 178
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$112
23%
upside
Avg. target
$125
38%
upside
High target
$143
58%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Goldman Sachs Paul Choi 30% 1-year accuracy 3 / 10 met price target | 58%upside $143 | Buy Initiated | 18 Dec 2024 |
Truist Securities Richard Newitter 74% 1-year accuracy 31 / 42 met price target | 32%upside $120 | Buy Reiterated | 8 Nov 2024 |
JMP Securities David Turkaly 29% 1-year accuracy 7 / 24 met price target | 23%upside $112 | Market Outperform Maintained | 7 Nov 2024 |
Financial journalist opinion
Positive
The Motley Fool
3 hours ago
2 Stock Market Predictions for 2025: 2 Stocks Worth Buying No Matter What Happens
In this video, Motley Fool contributors Jason Hall and Tyler Crowe make two predictions about the market in 2025, and also share two stock picks they think will do well no matter what happens with the market this year: Lantheus (LNTH -1.26%) and Synopsys (SNPS -0.99%).
Positive
Seeking Alpha
2 weeks ago
Lantheus Holdings: A Growing Business With Dominant Market Share
Lantheus Holdings (LNTH) is a profitable company with strong products like PYLARIFY and DEFINITY, both showing double-digit growth and dominant market share. Management has demonstrated excellent execution, particularly with PYLARIFY, which is on track to exceed $1 billion in sales by Q4 2024. The company is financially robust, with nearly $1 billion in cash, minimal debt, and strong operating cash flow, positioning it well for acquisitions.
Neutral
The Motley Fool
1 month ago
Why Lantheus Holdings Stock Won Big on Wednesday
Why Lantheus Holdings Stock Won Big on Wednesday
Neutral
GlobeNewsWire
1 month ago
Lantheus Announces Share Repurchase Program
BEDFORD, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announces that its board of directors has authorized a program to repurchase up to $250 million of its common stock during the next twelve months.
Neutral
GlobeNewsWire
1 month ago
Lantheus to Present at the Jefferies London Healthcare Conference
BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies London Healthcare Conference at 1:00 p.m. GMT (8 a.m. EST) on Wednesday, November 20.
Neutral
GlobeNewsWire
1 month ago
Lantheus Continues to Commend CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals and Reaffirms Outlook for PYLARIFY's Blockbuster Status for 2025
BEDFORD, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, notes that the Centers for Medicare & Medicaid Services (CMS) recently posted updated payment rates in Addendum B related to the final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The Company continues to commend CMS for recognizing the value of and ensuring broad patient access to specialized diagnostic radiopharmaceuticals. With PYLARIFY® (piflufolastat F 18) on track to exceed $1 billion in sales in 2024, Lantheus reaffirms its 2025 outlook for PYLARIFY as a blockbuster brand that will continue to be the clear standard and #1 ordered PSMA PET imaging agent in the U.S.
Positive
Seeking Alpha
1 month ago
Lantheus Holdings: Q3 Results Were Good But Market Overreacted
Lantheus, with a strong pharmaceutical portfolio and double-digit growth, fell 20% post-Q3 2024 due to expected weak Q4 EPS from temporary expenses. Key products Pylarify and Definity enhance diagnostic imaging for prostate cancer and heart conditions, respectively, with significant market potential and government support. Despite a conservative Q4 outlook, Lantheus' forward P/E of 13 and projected 15% annual revenue growth present an attractive buying opportunity.
Neutral
Seeking Alpha
1 month ago
Lantheus Holdings, Inc. (LNTH) Q3 2024 Earnings Call Transcript
Lantheus Holdings, Inc. (NASDAQ:LNTH ) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Mark Kinarney - VP of IR Brian Markison - CEO Paul Blanchfield - President Bob Marshall - CFO Jeff Humphrey - Chief Medical Officer Conference Call Participants Roanna Ruiz - Leerink Partners Anthony Petrone - Mizuho Group Richard Newitter - Truist Securities Matt Taylor - Jefferies Larry Solow - CJS Securities Tara Bancroft - TD Cowen Yuan Zhi - B. Riley Kemp Dolliver - Brookline Capital Markets Justin Walsh - Jones Trading Andy Hsieh - William Blair Ed Ridley-Day - Redburn Atlantic Operator Good morning.
Neutral
GlobeNewsWire
1 month ago
Lantheus Applauds CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care
BEDFORD, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, applauds the Centers for Medicare & Medicaid Services' (CMS) final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The rule, announced and detailed on the CMS website late Friday, recognizes the value of and ensures broad patient access to specialized diagnostic radiopharmaceuticals by improving the accuracy of payment amounts for these products.
Neutral
GlobeNewsWire
2 months ago
Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time
BEDFORD, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2024, to discuss its financial and operating results for the third quarter of 2024.
Charts implemented using Lightweight Charts™